Given the involvement of PGE2 in ALS inflammation and potential systemic side effects of COX-1 inhibition (COX-1 is constitutively expressed in most tissues), a variety of COX-2-inhibiting non-steroidal anti-inflammatory drugs (NSAIDs) have been tested for ALS therapeutics. This evidence concerns the gene PTGS1 and amyotrophic lateral sclerosis.